We respond to a BMJ Study that provides new estimates of breast cancer risks associated with HRT
Baroness Delyth Morgan, Chief Executive of Breast Cancer Now, responded to a BMJ Study which provides new estimates of breast cancer risks associated with HRT.
10 Nov 2020
Media StatementWe respond to news that the pandemic ‘threatens research as early career scientists look to leave’
Baroness Delyth Morgan, Chief Executive of Breast Cancer Now, was deeply concerned that 40% of charity-funded early career scientists have considered leaving research due to COVID-19.
10 Nov 2020
Media StatementWe support recommendations for faster and wider access to innovative cancer treatments
Mia Rosenblatt, Associate Director of Policy and Influencing at Breast Cancer Now, called for recommendations for faster and wider access to innovative cancer treatments.
09 Nov 2020
Media StatementWe welcome SMC approval of adjuvant Kadcyla and atezolizumab with nab-paclitaxel for use on the NHS
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, welcomed the Scottish Medicines Consortium's approval of adjuvant Kadcyla and atezolizumab with nab-paclitaxel, for use on the NHS.
09 Nov 2020
Media StatementWe respond to ‘plasmaMATCH’ trial that uses blood test to match women with breast cancer to a range of precision treatments
Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said the plasmaMATCH trial was an important development in the field of liquid biopsies.
11 Sept 2020